Company Overview and News

0
UDR / UDR, Inc. 8-K (Current Report)

2018-06-04 sec.gov
udr_Current_Folio_8-K - Investor_Presentation UNITED STATES SECURITIES AND EXCHANGE COMMISSION UDR

0
UDR / UDR, Inc. 8-K (Current Report)

2018-05-29 sec.gov
8-K - May 2018 - Proxy Votes and Bylaws UNITED STATES SECURITIES AND EXCHANGE COMMISSION
UDR

22
Somebody Bet On AvalonBay

2018-05-29 seekingalpha
REITs showing earnings growth, a strong balance sheet and a portfolio of properties in growing areas with high demand are best positioned for long-term growth.
UDR EQR ESS AVB MAA

5
Mispricing In The Multifamily Sector

2018-05-21 seekingalpha
Mispricing among multifamily REITs appears to be rampant at the moment with the higher multiple stocks corresponding to properties in locations that I view as more risky. Similarly, the companies with properties in high growth locations with strong fundamentals are trading toward the lower end of the FFO multiple spectrum. This mispricing provides investors the opportunity to buy strong fundamentals at a good value.
UDR APTS EQR

0
UDR / UDR, Inc. 10-Q (Quarterly Report)

2018-04-27 sec.gov
udr_Current_Folio_10Q Table of Contents
UDR

0
UDR / UDR, Inc. 10-Q (Quarterly Report)

2018-04-27 sec.gov
udr_Current_Folio_10Q Table of Contents
UDR

18
UDR Q1 FFO In Line With Expectations, Revenues Increase

2018-04-26 zacks
UDR Inc. (UDR - Free Report) reported funds from operations (FFO) as adjusted per share of 47 cents for first-quarter 2018, in line with the Zacks Consensus Estimate. The figure was higher than the prior-year quarter tally of 45 cents. Total revenues in the reported quarter rose 3.9% year over year to $253.3 million. Further, the top line came marginally above the Zacks Consensus Estimate of $253 million.
REG ARE UDR REG.PRG HCN REG.PRF ARE.PRD WELL.PRI WELL HCN.PRJ ARE.PRE HCN.PRI

0
UDR / UDR, Inc. 8-K (Current Report)

2018-04-25 sec.gov
udr_ER_Current_Folio_8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION
UDR

53
REITs to Watch for Earnings on Apr 25: AVB, DRE, PSA and UDR

2018-04-24 zacks
We are in the heart of the Q1 reporting cycle and the real estate investment trust (REIT) space is buzzing with activity. In fact, there is a deluge of Q1 earnings releases lined up for this week, of which AvalonBay Communities, Inc. (AVB - Free Report) , Duke Realty Corporation (DRE - Free Report) , Public Storage (PSA - Free Report) and UDR Inc. (UDR - Free Report) will release quarterly numbers on Apr 25.
PSA.PRA PSA.PRB DRE PSA.A RP UDR PSAXZ PSA.PRG PSA.PRE PSA.PRF AVB CBRE PSA.PRC PSA.PRD PSA.PRY PSA.PRZ PSA.PRW PSA.PRX PSA.PRU PSA.PRV PSA PSA.PRS PSA.PRT DRE.PRO CBG DRE.PRL

16
UDR to Post Q1 Earnings: What's in Store for the Stock?

2018-04-20 zacks
UDR Inc. (UDR - Free Report) is slated to report first-quarter 2018 results on Apr 25, after the market closes. Revenues and funds from operations (FFO) per share are expected to grow year over year. Last quarter, this Denver, CO-based residential real estate investment trust (REIT) delivered in-line FFO per share. Results reflected growth in revenues from same-store and stabilized non-mature communities.
TCO.PRK TCO.PRJ TCO PSB UDR SPG.PRJ PSB.PRV PSB.PRW SPG PSB.PRX PSB.PRY PSB.PRS PSB.PRT ROK PSB.PRU

0
UDR / UDR, Inc. DEF 14A

2018-04-09 sec.gov
2018 Proxy - DEF 14A
UDR

0
UDR / UDR, Inc. DEFA14A

2018-04-09 sec.gov
2018 Proxy Card - DEF A 14A UNITED STATES
UDR

15
UDR Rewards Investors With 4% Hike in Annualized Dividend

2018-03-28 zacks
Ushering in good news for its shareholders, UDR Inc. (UDR - Free Report) declared a 4% increase in annualized common dividend for 2018. The company will now pay a cash dividend of 32.25 cents per share for the first quarter compared with 31 cents paid in the prior quarter. The new dividend will be paid on Apr 30 to shareholders on record as of Apr 9. Based on this increased rate, annualized yield comes to about 3.
ABR SOHOL DB SOHOB SOHO EXR UDR ABRN ABRN.CL ABR.PRB SOHOM ABR.PRC ABR.PRA

0
UDR / UDR, Inc. PRE 14A

2018-03-19 sec.gov
2018 Proxy - DEF 14A
UDR

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

Silicon Investor Message Boards

This table lists all message boards related to UDR / UDR, Inc. on message board site Silicon Investor.

ALUDRA INC. Audre Recognition Systems
CUSIP: 902653104